The store will not work correctly when cookies are disabled.
8-(benzenesulfonyl)-3-(4-fluorophenyl)-1,4,8-triazaspiro[4.5]dec-3-en-2-one
ID: ALA5290689
Max Phase: Preclinical
Molecular Formula: C19H18FN3O3S
Molecular Weight: 387.44
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: O=C1NC2(CCN(S(=O)(=O)c3ccccc3)CC2)N=C1c1ccc(F)cc1
Standard InChI: InChI=1S/C19H18FN3O3S/c20-15-8-6-14(7-9-15)17-18(24)22-19(21-17)10-12-23(13-11-19)27(25,26)16-4-2-1-3-5-16/h1-9H,10-13H2,(H,22,24)
Standard InChI Key: JODVCLPEVQGBTH-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 30 0 0 0 0 0 0 0 0999 V2000
-0.8182 -0.8984 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1037 -0.4859 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6107 -0.8984 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6107 -1.7235 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.1037 -2.1360 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8182 -1.7235 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3250 -2.1359 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
2.0393 -1.7235 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7418 -2.7191 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.7374 -2.8501 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-1.5324 -1.3108 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.1508 -0.7397 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.8204 -0.0056 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.9966 -0.0979 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.9475 -0.9532 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.2327 0.7086 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0576 0.7089 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.4681 1.4214 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0555 2.1359 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.2349 2.1375 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.8186 1.4260 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.4680 2.8501 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
2.0395 -0.8987 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7520 -0.4881 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4666 -0.9007 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4681 -1.7213 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7566 -2.1376 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
3 2 1 0
4 3 1 0
5 4 1 0
1 6 1 0
6 5 1 0
4 7 1 0
7 8 1 0
7 9 2 0
7 10 2 0
1 11 1 0
11 12 1 0
12 13 1 0
14 13 2 0
1 14 1 0
12 15 2 0
16 13 1 0
17 16 2 0
18 17 1 0
19 18 2 0
20 19 1 0
16 21 1 0
21 20 2 0
19 22 1 0
23 8 2 0
24 23 1 0
25 24 2 0
26 25 1 0
27 26 2 0
8 27 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 387.44 | Molecular Weight (Monoisotopic): 387.1053 | AlogP: 1.93 | #Rotatable Bonds: 3 |
Polar Surface Area: 78.84 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 9.84 | CX Basic pKa: ┄ | CX LogP: 2.90 | CX LogD: 2.90 |
Aromatic Rings: 2 | Heavy Atoms: 27 | QED Weighted: 0.87 | Np Likeness Score: -1.40 |
References
1. Bhuiyan AI, Choi AH, Ghoshal S, Adiele UA, Dana D, Choi JY, Fath KR, Talele TT, Pathak SK.. (2023) Identification of a novel spirocyclic Nek2 inhibitor using high throughput virtual screening., 88 [PMID:37094724] [10.1016/j.bmcl.2023.129288] |